Exatecan Intermediate 2 (compound B) is a precursor used in the synthesis of Exatecan (DX-8951), an anticancer agent classified among the camptothecin analogs. Exatecan operates by interacting with DNA to disrupt the proliferation and division of tumor cells, effectively inhibiting tumor growth. It is primarily employed in research targeting various cancers, including ovarian, lung, and breast cancer.